Thanks for that pickup Vintage.
I just went back and checked because I had thought that efficacy of diagnosing stroke location and type was a part of the stage 2 endpoints although I got that wrong.... my mistake.
Given that clarification I agree with you that a commercial distribution partnership will likely follow the validation phase.
Thanks for that pickup Vintage.I just went back and checked...
-
- There are more pages in this discussion • 239 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EMV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.99 |
Change
-0.005(0.25%) |
Mkt cap ! $169.9M | |||
| Open | High | Low | Value | Volume |
| $1.98 | $1.99 | $1.94 | $30.91K | 15.75K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2562 | $1.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.99 | 2999 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| EMV (ASX) Chart |